Search

Your search keyword '"Freeman, Samuel S."' showing total 213 results

Search Constraints

Start Over You searched for: Author "Freeman, Samuel S." Remove constraint Author: "Freeman, Samuel S."
213 results on '"Freeman, Samuel S."'

Search Results

1. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy

2. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

4. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

5. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

6. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma

7. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

8. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells

9. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

10. Characterization of HPV and host genome interactions in primary head and neck cancers

11. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

12. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

13. The Cancer Genome Atlas Pan-Cancer analysis project

15. Genomic and immune profiling of pre-invasive lung adenocarcinoma

16. Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

17. Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

18. Supplementary Figures and Tables from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

19. Table S2 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

20. Supplementary Methods from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

21. Supplementary Figure Legends from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

22. Data from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

23. Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

24. Supplementary Figures 1-4 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

25. Supplementary Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

26. Supplementary Tables 1-8 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

27. Supplementary Figure 4 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

28. Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

29. Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

30. Supplementary Figure 5 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

31. Supplementary Figure 8 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

32. Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

33. Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

34. Supplementary Figure 7 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

35. Supplementary Figure 6 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

36. Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

37. Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

39. Characterization of HPV and host genome interactions in primary head and neck cancers

40. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients

41. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

42. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

43. Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

44. Abstract 2259: Predictive modeling of smoldering multiple myeloma progression to multiple myeloma by continuous variable analysis

45. GeneVector: Identification of transcriptional programs using dense vector representations defined by mutual information

46. Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

47. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

48. Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples

49. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women

50. Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with disease severity in hospitalized COVID-19 patients

Catalog

Books, media, physical & digital resources